JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Anagliptin (formerly known as SK0403) is a novel, potent, orally bioactive, highly selective inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC50 of 3.8 nM. It is less selective against DPP-8/9 (IC50 = 68, 60 nM). Anagliptin was approved for the treatment of type 2 diabetes mellitus in Japan in 2012. In addition to glycemic control, these agents showed beneficial effects on lipid metabolism in clinical trials. Anagliptin exhibited a lipid-lowering effect in a hyperlipidemic animal model, and suggested that the downregulation of hepatic lipid synthesis was involved in the effect. Anagliptin might have beneficial effects on lipid metabolism in addition to a glucose-lowering effect.
References: J Diabetes Investig. 2017 Mar; 8(2):155-160; Bioorg Med Chem. 2011 Dec 1; 19(23):7221-7.
Publications Citing Use of InvivoChem Anagliptin: ACS Omega 2021, 6, 11, 7771–7777https://doi.org/10.1021/acsomega.1c00242
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!